Brachytherapy Market Size & Share to Record New Values for the Forecast Period 2020-2030
Market Overview
Brachytherapy, also known as internal radiation therapy, is a type of radiotherapy in which radiation is delivered directly to a cancerous tumor in the body via a source placed close or next to it. The source emits gamma rays that target cancer cells while minimizing harm to healthy tissue nearby. Depending on the severity of the disease and its damage, brachytherapy is given at a Low Dose Rate (LDR) or a High Dose Rate (HDR). Small radioactive seeds are permanently implanted in or around the tumor in LDR, whereas radioactive sources are removed from the patient's body at the end of each session in HDR, which is utilized in high-risk tumors.
Brachytherapy Market: Key Players
Argon Medical Devices
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Becton
Dickinson and Company
Carl Zeiss Meditec AG
Eckert & Ziegler BEBIG S.A.
Elekta AB, iCAD Inc.
Isoray Inc.
Theragenics Corporation
iMedX Information Services
Varian Medical Systems Inc.
Growth Factor
Rising prevalence of different types of cancer
Brachytherapy has been shown to be an exceptionally successful treatment choice for cervical, skin, and breast cancers, which is fueling market expansion. Furthermore, the availability of high-quality brachytherapy equipment that delivers precise and very localized radiation doses to tiny tumors has increased patient and medical professional acceptance of the therapy.
Growing medical tourism
Growing medical tourism across the world, as well as increased knowledge of the benefits of brachytherapy, its cost-effectiveness, and higher cure rate when compared to surgery or external beam treatment (EBT), is propelling the industry forward.
Segmentation
By Technique
High Dose Rate Brachytherapy Devices
Low Dose Rate Brachytherapy Devices
By Application
Gynecologic Cancer
Prostate Cancer
Breast Cancer
Others
By End User:
Hospitals
Clinics
Clinical Laboratories
Academic Medical Centers
Others
Brachytherapy Market Dynamics
Brachytherapy Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
In 2020, the HDR brachytherapy category led the market, accounting for 71.2 percent of total revenue.
This category is predicted to develop due to the launch of innovative products such as GammaTile for the treatment of brain cancer. IsoRay gained FDA 510K approval for this device in July 2018, which employs Cesium-131 seeds, which have a lower risk of side effects than other regularly used LDR isotopes.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Brachytherapy Market growth?
Which segment accounted for the largest Brachytherapy Market share?
Who are the key players in the Brachytherapy Market?
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Brachytherapy, also known as internal radiation therapy, is a type of radiotherapy in which radiation is delivered directly to a cancerous tumor in the body via a source placed close or next to it. The source emits gamma rays that target cancer cells while minimizing harm to healthy tissue nearby. Depending on the severity of the disease and its damage, brachytherapy is given at a Low Dose Rate (LDR) or a High Dose Rate (HDR). Small radioactive seeds are permanently implanted in or around the tumor in LDR, whereas radioactive sources are removed from the patient's body at the end of each session in HDR, which is utilized in high-risk tumors.
Brachytherapy Market: Key Players
Argon Medical Devices
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Becton
Dickinson and Company
Carl Zeiss Meditec AG
Eckert & Ziegler BEBIG S.A.
Elekta AB, iCAD Inc.
Isoray Inc.
Theragenics Corporation
iMedX Information Services
Varian Medical Systems Inc.
Growth Factor
Rising prevalence of different types of cancer
Brachytherapy has been shown to be an exceptionally successful treatment choice for cervical, skin, and breast cancers, which is fueling market expansion. Furthermore, the availability of high-quality brachytherapy equipment that delivers precise and very localized radiation doses to tiny tumors has increased patient and medical professional acceptance of the therapy.
Growing medical tourism
Growing medical tourism across the world, as well as increased knowledge of the benefits of brachytherapy, its cost-effectiveness, and higher cure rate when compared to surgery or external beam treatment (EBT), is propelling the industry forward.
Segmentation
By Technique
High Dose Rate Brachytherapy Devices
Low Dose Rate Brachytherapy Devices
By Application
Gynecologic Cancer
Prostate Cancer
Breast Cancer
Others
By End User:
Hospitals
Clinics
Clinical Laboratories
Academic Medical Centers
Others
Brachytherapy Market Dynamics
Brachytherapy Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Recent News Related to Market
In 2020, the HDR brachytherapy category led the market, accounting for 71.2 percent of total revenue.
This category is predicted to develop due to the launch of innovative products such as GammaTile for the treatment of brain cancer. IsoRay gained FDA 510K approval for this device in July 2018, which employs Cesium-131 seeds, which have a lower risk of side effects than other regularly used LDR isotopes.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Brachytherapy Market growth?
Which segment accounted for the largest Brachytherapy Market share?
Who are the key players in the Brachytherapy Market?
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in Fatpos Global’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
1. EXECUTIVE SUMMARY
2. GLOBAL BRACHYTHERAPY MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL BRACHYTHERAPY MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL BRACHYTHERAPY MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL BRACHYTHERAPY MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Technique: Market Share (2020-2030F)
12.2.1. High Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Low Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Gynecologic Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Other cancers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Clinics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Academic medical centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Clinical Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
13.1. Argon Medical Devices
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Becton
13.3. Dickinson and Company
13.4. Carl Zeiss Meditec AG
13.5. Eckert & Ziegler BEBIG S.A.
13.6. Elekta AB, iCAD Inc.
13.7. Isoray Inc.
13.8. Theragenics Corporation
13.9. iMedX Information Services
13.10. Varian Medical Systems Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL BRACHYTHERAPY MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL BRACHYTHERAPY MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL BRACHYTHERAPY MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL BRACHYTHERAPY MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, South Korea, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Middle East and Africa: (Saudi Arabia, South Africa and rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Latin America (Brazil, Mexico, Rest of South America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Technique: Market Share (2020-2030F)
12.2.1. High Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Low Dose Rate Brachytherapy Devices, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Gynecologic Cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Prostate cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Breast cancer, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Other cancers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Clinics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Academic medical centers, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.4. Clinical Laboratories, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
13.1. Argon Medical Devices
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Becton
13.3. Dickinson and Company
13.4. Carl Zeiss Meditec AG
13.5. Eckert & Ziegler BEBIG S.A.
13.6. Elekta AB, iCAD Inc.
13.7. Isoray Inc.
13.8. Theragenics Corporation
13.9. iMedX Information Services
13.10. Varian Medical Systems Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
